Key facts
- This page summarizes David Michael Williams's Form 4 filing for Merck & Co., Inc. (MRK).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 May 2022, 17:44.
David Michael Williams - 03 May 2022 Form 4 Insider Report for Merck & Co., Inc. (MRK)
- Reporting relationship
- EVP,Chief Info&Digital Officer
- Issuer ticker
- MRK
- Reported as of
- 03 May 2022
- Net transaction value
- +$24,542
- SEC form
- 4
- Accepted by SEC
- 04 May 2022, 17:44:16 UTC
- Prior SEC filing
- 03 May 2022
- Next SEC filing
- 04 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kelly E. W. Grez as Attorney-in-Fact for David Michael Williams
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Michael Williams filed Form 4 for Merck & Co., Inc. (MRK) on 04 May 2022.
Change
- Previous filing in this sequence was filed on 03 May 2022.
- Current net transaction value: +$24,542.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRK
transaction
Common Stock
Options Exercise
- Transaction value
- $37,427
- Shares
- +427
- Change %
- +4.8%
- Price
- $87.65
- Shares after
- 9,410
- Date
- 03 May 2022
- Ownership
- Direct
MRK
transaction
Common Stock
Tax liability
- Transaction value
- $12,885
- Shares
- -147
- Change %
- -1.6%
- Price
- $87.65
- Shares after
- 9,263
- Date
- 03 May 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRK
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -427
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 03 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 427
- Exercise price
- Footnotes
- F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Holdings include shares acquired in dividend reinvestment transactions.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
Footnote F3
Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
Footnote F4
These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022.